Obicetrapib + Ezetimibe (FDC)
HeFH and/or ASCVD
Key Facts
About NewAmsterdam Pharma
NewAmsterdam Pharma's mission is to develop innovative oral therapies for cardiovascular and lipid-related diseases, targeting the large population of patients failing to achieve LDL-C goals. Its core achievement is the late-stage development of obicetrapib, a CETP inhibitor with compelling Phase 3 efficacy and safety data, supported by over $1.2 billion in total capital raised. The company's strategy involves securing regulatory approval, preparing for a U.S. launch, and leveraging ex-U.S. partnerships like the one with Menarini Group to maximize global commercial potential.
View full company profileAbout NewAmsterdam Pharma Company
NewAmsterdam Pharma is a Netherlands-based, NASDAQ-listed biotech dedicated to developing obicetrapib, a novel oral CETP inhibitor for cardiovascular and metabolic diseases. The company has rapidly advanced its lead asset through a robust Phase 3 program, securing major partnerships and over $1.2 billion in funding to date. Its strategy hinges on demonstrating obicetrapib's potent LDL-lowering efficacy and cardiovascular outcomes benefit to capture a multi-billion dollar market opportunity in high-risk patient populations inadequately served by statins and PCSK9 inhibitors.
View full company profile